Erkes et al. demonstrated that in order to effectively eliminate BRAFV600E melanoma (cell lines YUMM1.7 and D4M3.A) in C57BL/6 syngeneic mouse models, it was necessary to combine the CSF1R inhibitor PLX3397 with the tumor growth inhibitor PLX51107 for subsequent TAM depletion [157]. The gene discussed is CSF1R; the disease is melanoma.